Fig. 1 · Structure

Documents & Downloads

Wedelolactone

Cat. No. A14804 CAS 524-12-9

IKK Inhibitor II

Wedelolactone, a compound originally extracted from Eclipta alba, has been shown to inhibit caspase-11, which is a key regulator of proinflammatory cytokine IL-1β maturation and pathological apoptosis.

In Stock

Publications for Wedelolactone

1 publication citing this product

  1. Shigetoshi Yokoyama, .et al. , eLife, 2018, 7: e37854 PMID: 30526845

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In RANKL-stimulated RAW264.7 cells, wedelolactone reduced p65 phosphorylation and c-Fos/c-Src expression and limited NFATc1 nuclear localization. These cellular pathway results support modulation of NF-κB-associated osteoclast signaling; they do not demonstrate direct IKK binding or target selectivity. [1]

An additional biochemical activity was reported against purified proteasomes: chymotrypsin-like IC50 values were 9.97 μM for MDA-MB-231-derived 26S proteasome and 6.13 μM for bovine 20S proteasome. These assay-specific values do not establish selective action on IKK. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Caspase-11  
5-LOX IC50 2.5 μM
Apoptosis  

Cellular Effect

Cell Line Activity Value Description Reference
OVCAR-3 EC50 10.64 μM Inhibition of colony formation in human OVCAR-3 cells overexpressing G6PD incubated for 14 days by crystal violet staining based assay [PMID: 33689874]

Wedelolactone Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Wedelolactone from 2 published references. In vitro models include mouse pre-osteoclastic RAW264.7 cells stimulated with RANKL; human MDA-MB-231, MDA-MB-468 and T47D breast cancer cell lines.

Wedelolactone In Vitro Studies

After 10 h treatment of breast cancer cells, wedelolactone reduced chymotrypsin-like proteasome activity measured in cell extracts, with reported IC50 values of 27.8 μM in MDA-MB-231, 12.78 μM in MDA-MB-468 and 19.45 μM in T47D cells. These values describe proteasome activity after exposure, rather than cell killing. [2]

RANKL-associated NF-κB and NFATc1 signaling in RAW264.7 cells

Cell-based study · Mouse pre-osteoclastic RAW264.7 cells stimulated with RANKL [1]

Wedelolactone reduced RANKL-associated p65 phosphorylation, c-Fos and c-Src protein levels, and nuclear localization of NFATc1. These pathway readouts do not establish direct IKK binding or exclusive IKK dependence.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
p65 phosphorylation and c-Fos/c-Src protein levelsQualitative change Reduced relative to RANKL-only control; n=3; caption reports mean ± SD and *P<0.05, **P<0.01[1]
Nuclear localization of NFATc1Qualitative change Reduced with 2.5 μg/ml wedelolactone relative to RANKL-only control; n=3[1]

Literature-Reported Treatment Conditions

Treatment concentration
1.25, 2.5 and 5 μg/ml for Figure 4A; 2.5 μg/ml for Figure 4B
Exposure duration
6 d
Method
Exposure in culture medium; Western blot and NFATc1 immunofluorescence/nuclear fraction analysis
Co-treatment
30 ng/ml RANKL; comparisons include RANKL-only and unstimulated controls
Reported limits
Vehicle composition is not specified in the read Materials/cell assay methods. Replicate type is not defined beyond n=3 in the caption; no viability control for these signaling readouts was identified in the read sections.
Methods and source locations

Compound reported in the paper: Wedelolactone; Compound label in the paper: Wed

Evidence concerns the named compound used by the authors; equivalence of Adooq lots was not tested.

Figure 4A-B; corresponding Results; Materials and osteoclastogenesis, immunofluorescence and Western blot methods

p65 phosphorylation and c-Fos/c-Src protein levels: Immunoblotting with total p65 and GAPDH controls; no exact densitometry estimated from bars — Figure 4A and caption; osteoclast signaling Results

Nuclear localization of NFATc1: Immunofluorescence and nuclear/cytosolic immunoblotting; histone and GAPDH fraction controls — Figure 4B and caption; osteoclast signaling Results

Inhibition of purified 20S and 26S proteasome activity

Biochemical assay · 26S proteasome purified from human MDA-MB-231 cells; commercially supplied bovine 20S proteasome [2]

Wedelolactone inhibited substrate cleavage by isolated proteasomes, with the strongest reported activity against the chymotrypsin-like endpoint. This is an additional biochemical activity and does not establish IKK specificity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Chymotrypsin-like activity of purified 26S proteasomeIC50 9.97 μM[2]
Chymotrypsin-like activity of bovine 20S proteasomeIC50 6.13 μM[2]

Literature-Reported Treatment Conditions

Treatment concentration
5, 10, 25, 50 and 100 μM wedelolactone (Figure 2 legend)
Exposure duration
1 h at 37 °C
Method
Fluorogenic substrate cleavage by 5 μg purified 26S or 10 nM bovine 20S proteasome; 50 μM substrate
Vehicle
DMSO negative control; final DMSO fraction not specified
Co-treatment
10 μM MG132 positive control in separate assay mixtures
Reported limits
Confidence intervals for fitted IC50 values and final DMSO percentage not reported in the read sections; no compound fluorescence-interference counterscreen identified there.
Methods and source locations

Compound reported in the paper: Wedelolactone; Compound label in the paper: w

Evidence concerns the named compound used by the authors; equivalence of Adooq lots was not tested.

Results 2.2; Figure 2A-B and caption; Methods 4.1, 4.3.1-4.3.2, 4.10

Chymotrypsin-like activity of purified 26S proteasome: Suc-LLVY-AMC cleavage; nonlinear regression (GraphPad PRISM 6); Figure 2: three independent experiments, mean ± SD — Results 2.2; Figure 2A; Methods 4.3.2 and 4.10

Chymotrypsin-like activity of bovine 20S proteasome: Suc-LLVY-AMC cleavage; nonlinear regression; Figure 2: three independent experiments, mean ± SD — Results 2.2; Figure 2B; Methods 4.3.2 and 4.10

Proteasome activity after wedelolactone exposure in breast cancer cells

Cell-based study · Human MDA-MB-231, MDA-MB-468 and T47D breast cancer cell lines [2]

After 10 h exposure, lysates showed decreased proteasome substrate cleavage. Chymotrypsin-like IC50 values differed across the three cell lines. These are proteasome-activity endpoints after cell treatment, not cytotoxicity IC50 values.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Chymotrypsin-like proteasome activity after cell treatmentIC50 MDA-MB-231: 27.8 μM; MDA-MB-468: 12.78 μM; T47D: 19.45 μM[2]

Literature-Reported Treatment Conditions

Treatment concentration
5, 10, 25, 50 and 100 μM wedelolactone (Figure 1 legend)
Exposure duration
10 h cell exposure; lysate substrate cleavage measured for 1 h at 37 °C
Method
50 μg cell extract with 50 μM fluorogenic substrate; chymotrypsin-like endpoint uses Suc-LLVY-AMC
Vehicle
DMSO-treated control; final DMSO fraction not specified
Co-treatment
10 μM MG132 positive-control treatment in separate cultures
Reported limits
Fitted IC50 confidence intervals and final DMSO percentage not reported in the read sections; viability-normalized target engagement is not established by this lysate activity assay.
Methods and source locations

Compound reported in the paper: Wedelolactone; Compound label in the paper: w

Evidence concerns the named compound used by the authors; equivalence of Adooq lots was not tested.

Results 2.1; Figure 1A-C and caption; Methods 4.1-4.3.3 and 4.10

Chymotrypsin-like proteasome activity after cell treatment: Cell-extract Suc-LLVY-AMC cleavage; nonlinear regression; three independent experiments, mean ± SD — Results 2.1; Figure 1A-C and caption; Methods 4.3.3 and 4.10

Wedelolactone In Vivo Studies

In ovariectomized female C57BL/6 mice, wedelolactone at 10 mg/kg intraperitoneally every two days for four weeks, beginning two days after surgery, increased trabecular bone volume/tissue volume and trabecular number relative to vehicle-treated ovariectomized controls. The experiment tested prevention of bone loss in mice; vehicle composition and endpoint-specific attrition were not specified. [1]

Trabecular bone outcomes in ovariectomized mice

Animal study · Nine-week-old female C57BL/6 mice, ovariectomized or sham operated [1]

Wedelolactone increased trabecular bone volume/tissue volume and trabecular number relative to vehicle-treated ovariectomized mice. Results support attenuation of bone loss in this preventive mouse model; normalization to sham and clinical efficacy were not established.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Bone volume/tissue volume and trabecular numberDirection versus OVX vehicle Both increased with wedelolactone; *P<0.05 for OVX versus OVX+Wed in Figure 5A; n=5–6; mean ± SD[1]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Every two days
Treatment course
Four weeks, starting two days after ovariectomy
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
OVX + Wed
10 mg/kg
Vehicle-treated OVX mice; sham-operated mice provide the baseline comparator. Six mice assigned per group; Figure 5A n=5–6.Trabecular bone volume/tissue volume and trabecular number increased versus OVX vehicle (*P<0.05).[1]
OVX + Wed
Model: Nine-week-old female C57BL/6 mice, ovariectomized or sham operated
Reported limits: Vehicle composition and injection volume not specified in the read methods. Methods assign six mice per group; Figure 5A reports n=5–6 without endpoint-specific attrition reasons. Randomization and blinding were not described in the read animal methods.
Methods and source locations

Compound reported in the paper: Wedelolactone; Compound label in the paper: Wed

Evidence concerns the named compound used by the authors; equivalence of Adooq lots was not tested.

Figure 5A; in vivo Results; ovariectomized mouse model and bone histomorphometric methods

Bone volume/tissue volume and trabecular number: Bone histomorphometric analysis; exact bar values not transcribed or estimated — Figure 5A and caption; in vivo Results

OVX + Wed · Figure 5A and caption; in vivo Results and animal methods

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 524-12-9
Applications IKK Inhibitor II
Formula C16H10O7
Molecular Weight 314.3
Synonyms IKK Inhibitor II; Eclipta alba
SMILES
COC1=CC(=C2C(=C1)OC(=O)C3=C2OC4=CC(=C(C=C43)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 60 mg/mL (190.92 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Wedelolactone Research References

  1. [1] Liu YQ, Hong ZL, Zhan LB, et al. Wedelolactone enhances osteoblastogenesis by regulating Wnt/β-catenin signaling pathway but suppresses osteoclastogenesis by NF-κB/c-fos/NFATc1 pathway. Scientific reports (2016). PMID: 27558652 DOI: 10.1038/srep32260 Source material
  2. [2] Nehybová T, Šmarda J, Daniel L, et al. Wedelolactone Acts as Proteasome Inhibitor in Breast Cancer Cells. International journal of molecular sciences (2017). PMID: 28353647 DOI: 10.3390/ijms18040729 Source material

Publications

1 publication citing this product

  1. Shigetoshi Yokoyama, .et al. , eLife, 2018, 7: e37854 PMID: 30526845

Added to your cart

View Cart Checkout
Loading...